Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Halabi S, et al. Among authors: tangen cm. Ann Oncol. 2020 Jul;31(7):930-941. doi: 10.1016/j.annonc.2020.03.309. Epub 2020 Apr 11. Ann Oncol. 2020. PMID: 32289380 Free PMC article.
Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.
Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA. Umbehr MH, et al. Among authors: tangen cm. Prostate Cancer Prostatic Dis. 2015 Sep;18(3):264-9. doi: 10.1038/pcan.2015.19. Epub 2015 May 5. Prostate Cancer Prostatic Dis. 2015. PMID: 25939516 Free PMC article.
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Hussain M, et al. Among authors: tangen c. J Clin Oncol. 2009 May 20;27(15):2450-6. doi: 10.1200/JCO.2008.19.9810. Epub 2009 Apr 20. J Clin Oncol. 2009. PMID: 19380444 Free PMC article. Clinical Trial.
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.
Lara PN Jr, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. Lara PN Jr, et al. Among authors: tangen c. Cancer Treat Res Commun. 2018;16:18-23. doi: 10.1016/j.ctarc.2018.04.005. Epub 2018 Apr 28. Cancer Treat Res Commun. 2018. PMID: 31298998 Free PMC article.
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
Smith DC, Tangen CM, Van Veldhuizen PJ Jr, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MH. Smith DC, et al. Among authors: tangen cm. Urology. 2011 May;77(5):1172-6. doi: 10.1016/j.urology.2010.12.043. Epub 2011 Feb 21. Urology. 2011. PMID: 21334731 Free PMC article. Clinical Trial.
310 results